Orthocell (ASX:OCC) is set to kick off sales in Germany, Austria and Switzerland for its dental guided bone and tissue regeneration product Striate+, gaining exposure to a market valued over $1 billion. 

Watch the video to hear more.

 

This video was developed in collaboration with Orthocell, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Read MoreDrug DevelopmentHealthMedtech

Featured Companies

You might be interested in